Beta Bionics BBNX 深 滬
等待開盤 11-05 09:30:00 美东时间
16.19
+1.090
+7.22%
華盛通- 最 高16.835
- 今 開15.18
- 成交量 34.83万股
- 最 低 15.18
- 昨 收 15.10
- 總市值 8.80亿
- 52周最高 32.71
- 市盈率 靜 --
- 換手率 0.64%
- 52周最低 8.80
- 委 比 80.18%
- 總股本 5436.71万
- 歷史最高 32.71
- 量 比 0.52
- 振 幅 10.96%
- 歷史最低 8.80
- 每 手 1
- 風險率 6.50%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Beta Bionics Announces Participation at Upcoming Investor Conferences
Beta Bionics, Inc. announced that its management team will participate in several upcoming investor conferences in November and December 2026. Presentations will be held at the Wolfe Research Healthcare Conference on November 10, the Stifel Healthcare Conference on November 11, the Jefferies Global Healthcare Conference in London on November 18-19, and the Piper Sandler Healthcare Conference on December 2. All presentations will be available live...
11-03 12:30
Beta Bionics收跌5.07%，成交额1296.89万美元
11月3日，Beta Bionics（BBNX）收跌5.07%，报15.9美元，成交额1296.89万美元，市值8.64亿美元。 行情数据 • 开盘价：16....
11-03 06:48
Beta Bionics Earnings Call: Mint Clearance Fuels Growth
Beta Bionics, Inc. (($BBNX)) has held its Q3 earnings call. Read on for the mai...
11-01 08:22
美股大行评级 | 潜在涨幅163.5%！BTIG上调Cullinan Therapeutics目标价至41美元，维持"买入"评级
今日重点评级关注：BTIG：维持Cullinan Therapeutics"买入"评级，目标价从40美元升至41美元；Rosenblatt：维持SK海力士"买入"评级，目标价从320美元升至400美元
10-29 12:30
Beta Bionics第三季度营收增长30%，2026年展望收窄
Beta Bionics公布2026财年第三季度营收同比增长30%至3550万美元，收窄了全年营收指引，并详细说明了与Mint相关的营收递延情况及产品计划。
10-28 09:11
Beta Bionics Q3 Revenue Rises 30%, 2026 Outlook Narrows
Beta Bionics posted 30% Q3 2026 revenue growth to $35.5 million, narrowed full-year revenue guidance and detailed Mint-related revenue deferrals and product plans.
10-28 09:11
Beta Bionics (BBNX) 2026年第三季度业绩电话会：Mint发布与上调营收指引
Beta Bionics 2026年第三季度财报电话会：销售额增长30%至3550万美元，上调2026年业绩指引，Mint的推出计划仍定于2027年第一季度。
10-28 08:04
Beta Bionics shares are trading lower after the company reported Q3 financial results. The company may be experiencing a sell-the-news selloff.
Beta Bionics shares are trading lower after the company reported Q3 financial results. The company may be experiencing a sell-the-news selloff.
10-28 05:14
Beta Bionics Raises FY2026 Sales Guidance from $121.000M-$126.000M to $124.000M-$126.000M vs $126.626M Est
Beta Bionics (NASDAQ:BBNX) raises FY2026 sales outlook from $121.000 million-$126.000 million to $124.000 million-$126.000 million vs $126.626 million estimate.
10-28 04:03
Beta Bionics Q3 EPS $(0.52) Beats $(0.53) Estimate, Sales $35.505M Beat $34.722M Estimate
Beta Bionics (NASDAQ:BBNX) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.53) by 1.89 percent. This is a 57.58 percent decrease over losses of $(0.33) per share from the same period last year. The company reported quarterly sales of $35.505 million wh...
10-28 04:02
